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Lifelong quercetin enrichment and cardioprotection in Mdx/Utrn+/− mice 
Abstract 
Duchenne Muscular Dystrophy (DMD) is associated with progressive cardiac pathology, however, the 
SIRT1/PGC1-α activator quercetin may cardioprotect dystrophic hearts. We tested the extent to which 
long term 0.2% dietary quercetin enrichment attenuates dystrophic cardiopathology in Mdx/Utrn+/- mice. 
At 2 months, Mdx/Utrn+/- mice were fed quercetin enriched (Mdx/Utrn+/--Q) or control diet (Mdx/Utrn+/-) 
for 8 months. Control C57BL/10 (C57) animals were fed a control diet for 10 months. Cardiac function 
was quantified by MRI at 2 and 10 months. Spontaneous physical activity was quantified during the last 
week of treatment. At 10 months hearts were excised for histological and biochemical analysis. Quercetin 
feeding improved various physiologic indices of cardiac function in diseased animals. Mdx/Utrn+/--Q also 
engaged in more high intensity physical activity than controls. Histological analyses of heart tissues 
revealed higher expression and co-localization of utrophin and α-sarcoglycan. Lower abundance of 
fibronectin, cardiac damage (Hematoxylin Eosin-Y), and MMP9 were observed in quercetin fed versus 
control Mdx/Utrn+/- mice. Quercetin evoked higher protein abundance of PGC-1α, cytochrome-c, ETC 
complexes I-V, citrate synthase, SOD2, and GPX compared to control-fed Mdx/Utrn+/-. Quercetin 
decreased abundance of inflammatory markers including NFκB, TGF-β1, and F4/80 compared to Mdx/
Utrn+/-, however, P-NFκB, P-IKBα, IKBα, CD64 and COX2 were similar between groups. Dietary quercetin 
enrichment improves cardiac function in aged Mdx/Utrn+/- mice, increases mitochondrial protein content, 
and dystrophin glycoprotein complex formation. Histological analyses indicate a marked attenuation in 
pathological cardiac remodeling and indicate that long term quercetin consumption benefits the 
dystrophic heart. 
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Duchenne Muscular Dystrophy (DMD) is associated with progressive cardiac pathology, however, the 45 
SIRT1/PGC1-α activator quercetin may cardioprotect dystrophic hearts. We tested the extent to which 46 
long term 0.2% dietary quercetin enrichment attenuates dystrophic cardiopathology in Mdx/Utrn+/- mice. 47 
At 2 months, Mdx/Utrn+/- mice were fed quercetin enriched (Mdx/Utrn+/--Q) or control diet (Mdx/Utrn+/-) 48 
for 8 months. Control C57BL/10 (C57) animals were fed a control diet for 10 months. Cardiac function 49 
was quantified by MRI at 2 and 10 months. Spontaneous physical activity was quantified during the last 50 
week of treatment. At 10 months hearts were excised for histological and biochemical analysis. Quercetin 51 
feeding improved various physiologic indices of cardiac function in diseased animals. Mdx/Utrn+/--Q also 52 
engaged in more high intensity physical activity than controls. Histological analyses of heart tissues 53 
revealed higher expression and co-localization of utrophin and α-sarcoglycan. Lower abundance of 54 
fibronectin, cardiac damage (Hematoxylin Eosin-Y), and MMP9 were observed in quercetin fed versus 55 
control Mdx/Utrn+/- mice. Quercetin evoked higher protein abundance of PGC-1α, cytochrome-c, ETC 56 
complexes I-V, citrate synthase, SOD2, and GPX compared to control-fed Mdx/Utrn+/-. Quercetin 57 
decreased abundance of inflammatory markers including NFκB, TGF-β1, and F4/80 compared to 58 
Mdx/Utrn+/-, however, P-NFκB, P-IKBα, IKBα, CD64 and COX2 were similar between groups. Dietary 59 
quercetin enrichment improves cardiac function in aged Mdx/Utrn+/- mice, increases mitochondrial 60 
protein content, and dystrophin glycoprotein complex formation. Histological analyses indicate a marked 61 
attenuation in pathological cardiac remodeling and indicate that long term quercetin consumption benefits 62 
the dystrophic heart. 63 
 64 
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 66 
Novel findings: The current investigation provides first time evidence that quercetin provides physiologic 67 
cardioprotection against dystrophic pathology and is associated with improved spontaneous physical 68 
activity. Secondary findings suggest that quercetin-dependent outcomes are in part due to PGC-1α 69 
pathway activation. 70 
 71 




Duchenne muscular dystrophy (DMD) is a juvenile musculoskeletal genetic disease of dystrophin 74 
deficiency. DMD is caused by a loss of functional dystrophin protein expression due to a nonsense 75 
mutation (11) and affects 1 in 3,500 males resulting in a progressive loss of muscle function and 76 
premature death (16). Physiologically, DMD is evident by muscle atrophy and weakness with a wide 77 
range of heterogeneity. Disease progression is marked by muscle degeneration and inadequate 78 
regeneration leading to respiratory and cardiac complications. Failure of the diaphragm and accessory 79 
respiratory muscles commonly cause death in many patients resulting in early mortality (15). Due to 80 
improvements in care, the average life span of DMD patients has extended to the point that cardiac 81 
pathology accounts up to 40% of all deaths (9). As cardiac health deteriorates, cardiac complications 82 
manifest as ECG abnormalities, cardiac remodeling, contractile dysfunction, fibrotic tissue deposition, 83 
ventricular dilation, and heart failure (17). Accordingly, countermeasures directed against cardiac 84 
pathology in the DMD heart are needed.  85 
Several mouse models of DMD exist as first step in the scientific vetting of potential therapeutics for 86 
DMD. The dystrophin deficient mdx mouse is currently the most investigated animal model, though 87 
disease severity and lifespan in the mdx mouse imperfectly recapitulate the human condition.(14, 40) In 88 
contrast, the Mdx/Utrn+/- mouse is a comparatively less studied model of murine DMD that exhibits an 89 
exacerbated pathology and reduced life span. The Mdx/Utrn+/- mouse lacks dystrophin and is a 90 
heterozygous knockout for utrophin, a dystrophin like protein, which appears to alleviate DMD pathology 91 
if upregulated and may partially replace dystrophin deficiency in mdx mice.(41) Furthermore, aged 92 
Mdx/Utrn+/- mice exhibit accelerated declines in cardiac health and dystrophic pathology.(50)  93 
Prior work clearly indicates that DMD is a multifaceted disease whereby inflammation, mitochondrial 94 
dysfunction, and oxidative stress work in concert to promote cardiac pathology. Accordingly, 95 
countermeasures directed against individual disease facets including anti-inflammatory agents, (17) and 96 
antioxidant administration(51) attenuate cardiac dysfunction. While ‘cocktail therapies’ are currently used 97 
in clinical settings to counter individual aspects of DMD, a single counter measure remains elusive. New 98 
findings suggest that a class of flavanones (primarily plant-derived polyphenols) may be effective as a 99 
single therapeutic agent in blunting the pathological mechanisms associated with dystrophic 100 
cardiopathology.  101 
Polyphenols effectively combat chronic inflammation,(7) cardiac pathology,(20) oxidative stress(48) and 102 
induce adaptive gene expression through activation of SIRT1/PGC-1α (24, 27). This latter point is a 103 
fundamental mechanism underpinning the benefits of polyphenol use. Early published findings suggest 104 
that polyphenols promote induction of adaptive gene transcripts including the SIRT1/PGC-1α axis that 105 
promotes upregulation of mitochondrial endogenous antioxidant enzyme and oxidative enzyme content in 106 
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addition to utrophin expression.(22) In support, activation of this pathway may attenuate dystrophic 107 
pathology in limb muscle as examined with prevention(21, 38) and rescue(22, 23) approaches. Quercetin 108 
(3,3’,4’,5,7-pentahydroxyflaone) ingestion comprises a majority of the total polyphenol ingestion in the 109 
normal diet(8) and has gained recent attention as a potential dietary therapeutic. Quercetin is a naturally 110 
occurring, flavonol with inherent anti-inflammatory, direct antioxidant effects, and is a potent 111 
SIRT1/PGC-1α activator. Recent work from our lab group suggests that six months of dietary quercetin 112 
enrichment (0.2%) elevated bioavailable quercetin levels in blood plasma and may serve as a 113 
countermeasure against dystrophic muscle pathologies.(24) Moreover, published data from our lab 114 
suggests that short term dietary quercetin enrichment promotes mitochondrial biogenesis, endogenous 115 
antioxidant protein abundance, and utrophin expression in young mdx mice. Histological analyses further 116 
indicated that quercetin consumption, was also associated with lower matrix metalloprotease-9 (MMP-9) 117 
expression in young mdx mouse hearts and attenuated cardiac and fibrotic damage in older mdx mice.(3) 118 
While early findings are compelling, it is unknown whether long term dietary quercetin enrichment also 119 
translates to improved physiologic outcomes. Given these unknowns and the need to explore novel 120 
therapeutic approaches in the context of more severe mouse models of DMD, we undertook the current 121 
investigation of quercetin efficacy using the Mdx/Utrn+/- mouse model. Experimental considerations 122 
included chronic quercetin treatment from 2 months to 10 months of age, incorporation of high resolution 123 
MRI cardiac scans, quantification of spontaneous physical activity in senescent animals, and a 124 
comprehensive examination of histological and biochemical post mortem outcomes in the resulting 125 
cardiac tissues. We hypothesized that long term dietary quercetin enrichment would elicit improved 126 
cardiac function, PGC-1α expression and mitochondrial protein content. In addition, we hypothesized that 127 
quercetin-fed mice would exhibit less deleterious tissue remodeling and inflammation than control-fed 128 
counterparts. Finally, we hypothesized that quercetin-fed mice would exhibit improved physical activity 129 




Study design and animals 132 
The experimental protocol was submitted to and approved by the Auburn University Animal Care and 133 
Use Committee and was in accordance with the American Physiological Society. To complete these 134 
experiments 2 month old dystrophin deficient mice heterozygous for a utrophin mutation (Mdx/Utrn+/-, 135 
stock#014563; derived from female homozygous Utrntm1Ked allele/Dmdmdx allele and male homozygous 136 
Utrntm1Ked allele/hemizygous Dmdmdx allele) and respective C57BL/10SnJ (stock# 000666) mice of the 137 
same background strain were purchased from Jackson Laboratories (Jackson Laboratory, Bar Harbor, 138 
Maine). During experimentation, all animals were housed on a 12h-12h reverse light-dark cycle. Prior to 139 
the initiation of the experiment all mice were maintained on the same AIN93 diet (Bioserve, Flemington, 140 
NJ) diet. At 2 months of age, Mdx/Utrn+/- mouse diets consisted of either AIN93 diet (Mdx/Utrn+/-, n=8), 141 
AIN93 diet or an identical AIN93 diet fortified with 0.2% quercetin-fortified rodent chow (Mdx/Utrn+/--142 
Q, n=8) (Bioserv Inc., Frenchtown, NJ). Control C57/BL10 mice were fed the AIN93 control rodent 143 
chow diet (C57, n=8) for the 8 months total experimentation time. All water and food were provided ad 144 
libitum throughout the experimentation period.  145 
Functional cardiac assessment (MRI) 146 
To assess cardiac function, mice were scanned at 2 months and 10 months of age using a 7 Telsa (7T) 147 
magnetic resonance imaging (MRI) (Siemens, Erlangen, DE). Prior to scanning, mice were anesthetized 148 
and maintained with isoflurane during the scan. Cardiac and respiratory rates were monitored with ECG 149 
and respiration leads. A rectal temperature probe was used to monitor core temperature which was 150 
maintained with a heating pad at 37°C for all cardiac scans. All mice were maintained under anesthesia 151 
during the scanning processes via isoflurane. For cardiac scans, all mice were anesthetized with 1% 152 
isoflurane, instrumented for ECG and respiration, placed in a custom made quadrature radio frequency 153 
coil, and had body temperature maintained at 37±1 C. Prospectively-gated dark-blood cardiac images 154 
were acquired as orthoganal2-chamber and 4-chamber long-axes, and transverse mid-ventricular short-155 
axis slices for 3-dim representation of the entire heart. Scan parameters included field of view = 32x32 156 
mm, slice thickness = 1 mm, matrix = 128x128, pixel size = 0.25x0.25 mm, and cine phases = 20. 157 
Cardiac performance was assessed by two trained analysts under blinded conditions. Cinematic audio 158 
video interleaves (AVIs) were created to show real-time heart function and aid in determination of end-159 
systole (ES) and end-diastole (ED) points. Cardiac ES and ED volumetric geometries and left-ventricular 160 
wall thickness were quantified using Image J software (NIH, Bethesda, MD).(5) For each cardiac 161 
variable, correlation analyses were performed to document agreement between blinded analysts (data not 162 
shown). Resulting cardiac data from each analyst for each variable were averaged for final data point 163 
determination.  164 
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MRI T2 mapping of the entire heart was performed as an indirect metric of tissue edema in the 165 
10 month old scans. T2 maps were acquired as a stack of 6-8 short axis slices at TE=10, 20, 40 166 
and 60 ms, TR = 1500 ms, and other parameters same as above for cine scans.  Myocardial tissue 167 
T2 estimates were calculated from subsequent per-pixel, 4-point, monoexponential curve-fit to 168 
the T2 map images.  169 
Quantification of spontaneous physical activity 170 
During the final week of treatment, Mdx/Utrn+/- mice from control- and quercetin-fed groups were 171 
observed for instances of sitting, grooming, eating/drinking, socializing, standing, walking, wall pacing, 172 
running, and jumping. This technique represents an ethogram (repertoire of typical animal activities) 173 
using “0-1 recording” method applied across many species.(29) As such, the observance of a mouse 174 
performing a particular activity (sitting, grooming, etc.) was recorded as 1. Activity counts were 175 
performed on two occasions by two investigators where activity recordings were made in 15 second 176 
blocks for a duration of 10 minutes resulting in a total of 40 time periods per observation session. Thus, 177 
for the two recording sessions, 20 total minutes of activity were recorded. Activity counts were performed 178 
at a common time at the end of the photo light and photo dark housing cycles and resulting scores were 179 
averaged. Total activity counts were calculated as n=1/activity, minimum of 40/session. Moreover, to 180 
gauge total activity in a single metric, total activity counts for each activity were scaled for the relative 181 
metabolic demand and summed into a final value. Specifically, the metric was scaled to the approximate 182 
metabolic costs of the various activities (sitting, grooming = 1, eating/drinking, socializing, and standing 183 
= 1.5, walking and wall pacing = 2, running = 2.5, jumping =3). As such, higher metric scores are 184 
reflective of engagement in more high intensity activities.  185 
Tissue harvesting and storage 186 
After the 10 month longitudinal experiment, mice were weighed, and anaesthetized with isoflurane until a 187 
surgical plane was established and mice were sacrificed via cardiac excision. Hearts were rinsed in chilled 188 
10mM PBS, weighed, placed in optimum cutting temperature compound (OCT), and frozen in 2-methyl-189 
butane chilled by liquid nitrogen to reduce risk of freeze fracture. After freezing, hearts were stored at -190 
80°C until further analysis. 191 
Histology and immunofluorescence 192 
Hearts were cut 10 µm-15 µm thick on a Shandon Cryotome cryostat (-30°C) and set on 1 mm positively 193 
charged microscope slides (Fischer Scientific, Pittsburgh, PA, USA). To assess for total cardiac damage, 194 
slides were stained by a Hematoxylin and Eosin-Y histological procedure. Accordingly, stained slides 195 
were imaged via light microscopy with Nikon software (Melville, NY, USA). 10-15 images were 196 
obtained per slide at a magnification of 40x to characterize and confirm consistent representation of each 197 
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cardiac cross section. Images were then analyzed using Image J software (NIH, Bethesda, MD, USA). 198 
Results of all images were quantified to the total damaged tissue to total healthy tissue (μm2). All imaging 199 
and analysis was conducted under blinded conditions. 200 
Cardiac expression of utrophin, fibronectin, metalloprotease 9 (MMP9), α-Sarcoglycan, and co-201 
localization of α-Sarcoglycan and utrophin were determined using a histological immunofluorescence 202 
detection procedure. Briefly, slides were fixed with a 10% formalin solution, rinsed, and permeabilized 203 
with a Triton X-100 in 1% sodium citrate solution. Slides were rinsed in 10mM PBS and blocked with a 204 
3% bovine serum albumin and 20% goat or mouse serum solution. Slides were incubated with primary 205 
antibodies for proteins of interest: (Fibronectin, 1:500 dilution; F3648; Sigma-Aldrich), (Utrophin, 1:500 206 
dilution; sc-33700; Santa Cruz Biotechnology), (α-Sarcoglycan, 1:500 dilution; sc-28278; Santa Cruz 207 
Biotechnology) MMP9, 1:500 dilution; sc-6840; Santa Cruz Biotechnology). Heart sections were then 208 
incubated with corresponding secondary antibodies for Texas Red (TRITC, 1:500; T1-1000; Vector 209 
Laboratories Inc.) and/or fluorescein isothiocyanate (FITC) (1:500, sc-2365; Santa Cruz Biotechnology) 210 
(1:500, sc-2010; Santa Crus Biotechnology) fluorescent  tags. Slides were sealed with 4’,6-diamidino-2-211 
phenylindole (DAPI) (Vector Laboratories Inc.) mounting medium and imaged with a fluorescent 212 
microscope (Nikon, Melville, NY). Random images (10-15) were obtained as previously discussed with 213 
corresponding DAPI, FITC, and TRITC filters. Images were analyzed for mean fluorescent positive 214 
pixels were quantified to the examined area (μm2) using Nikon Software (Nikon, Melville, NY). All 215 
imaging and analyses were conducted under blinded conditions. 216 
Western blotting 217 
Heart protein (50μg/sample) was obtained from heart samples and separated using standard SDS-PAGE 218 
techniques on 6%-17% polyacrylamide gels through electrophoresis. Proteins were transferred to 219 
polyvinylidene difluoride (PVDF) membranes and stained and imaged with Ponceau stain to ensure equal 220 
loading. Membranes were exposed to primary antibodies for each protein of interest: (PGC-1α, 1:500 221 
dilution; sc-13067; Santa Cruz Biotechnology), (SOD2, 1:500; sc-30080; Santa Cruz Biotechnology), 222 
(Citrate Synthase, 1:500 dilution; sc-390693; Santa Cruz Biotechnology), (Cytochrome-C, 1:500 dilution; 223 
sc-7159; Santa Cruz Biotechnology), (Glutathione peroxidase, 1:500; sc-74498; Santa Cruz 224 
Biotechnology), (CD64, 1:500 dilution, sc-15364p; Santa Cruz Biotechnology), .), (F4/80, 1:200 dilution; 225 
sc-25830; Santa Cruz Biotechnology), (Cyclooxygenase 2, 1:1000; CS-12282; Cell Signaling Technology 226 
Inc.), (NFκB, 1:1000 dilution; CS-8242; Cell Signaling Technology Inc.), (Phospho-NFκB, 1:1000 227 
dilution; CS-3033; Cell Signaling Technology Inc.), (IκBα, 1:1000 dilution; CS-4814; Cell Signaling 228 
Technology Inc.), (Phospho-IκBα, 1:1000 dilution; CS-2859; Cell Signaling Technology Inc.), (OxPhos 229 
Complex Kit, 1:5000 dilution; 457999; Invitrogen), (TGFβ-1, 1:500 dilution; sc-146; Santa Cruz 230 
Biotechnology). Membranes were then exposed to corresponding HRP-conjugated secondary antibodies 231 
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for chemiluminescence detection: (anti-rabbit IgG HRP linked, 1:1000 dilution; CS-7074; Cell Signaling 232 
Technology Inc.), (anti-mouse IgG HRP linked, 1:1000 dilution; CS-7076: Cell Signaling Technology 233 
Inc.). Membranes were reprobed and exposed to corresponding normalizing protein primary antibodies: 234 
(GAPDH, 1:1000, GenTex) or (α- Tubulin, 1:1000 dilution; DHSB). Corresponding secondary antibodies 235 
previously mentioned were used for chemiluminescence detection. Western blots were normalized to 236 
corresponding normalizing protein, Ponceau stain, and were analyzed using a UVP LLC digital imaging 237 
device (Upland, CA, USA). All experiments and analysis were conducted by a blinded laboratory 238 
technician. 239 
Statistical analyses 240 
End point measures were analyzed by one way ANOVA. A two-way (strain x treatment) repeated 241 
measures (2 month x 10 month) ANOVA was used to test differences in cardiac function using SPSS 20 242 
(IBM, New York City). Tukey post-hoc analyses were performed as indicated. Significance was set at p ≤ 243 




Animal characteristics 246 
Animal characteristics and measurements are presented in [Table 1]. At the end of the treatment periods 247 
Mdx/Utrn+/- and Mdx/Utrn+/--Q mice were heavier than C57 controls (p<0.001). Heart weights were 248 
higher in Mdx/Utrn+/- mice compared to C57 (p=0.006). Heart weights normalized to body weight (mg/g) 249 
from Mdx/Utrn+/--Q mice were lower than those from C57 mice (p=0.001). 250 
Cardiac function 251 
MRI cardiac function at 2 month and 10 month time points are presented in [Table 2]. For C57, untreated 252 
Mdx/Utrn+/- and Mdx/Utrn+/--Q mice, representative T1 dark blood cine images of 10 month old heart 253 
scans are presented in Figure 1. Representative images include mid-ventricular short axis views at end 254 
diastolic (ED) and end systolic (ES) time frames. Analysis of 2 month baseline measurements indicate no 255 
differences existed between group for 9 of the 11 cardiac performance measures including ejection 256 
fraction (EF), stroke volume (SV), cardiac output (CO), end systolic volume (ESV), left ventricular end 257 
diastolic dimension (LVEDD), fractional shortening (%FS), systolic wall thickness (SWT) and %SWT. 258 
As an exception and in a strain-dependent fashion, end diastolic volume (EDV) at the 2 month analysis 259 
was lower in Mdx/Utrn+/- and Mdx/Utrn+/--Q mice while HR was higher. Inexplicably, left ventricular end 260 
systolic dimension (LVESD) was lower in Mdx/Utrn+/- versus C57 and Mdx/Utrn+/--Q mice at the 2 261 
month baseline measurement. Similar to the 2 month assessment, HR was higher in 10 month old 262 
Mdx/Utrn+/- and Mdx/Utrn+/--Q as compared to C57. No other strain-dependent cardiac differences were 263 
observed at the 10 month time point. Moreover, of the cardiac variables determined currently, only ESV 264 
and LVESD were indicative of diminished cardiac function in Mdx/Utrn+/- mice. In contrast, and 265 
suggestive of improved cardiac function at the 10 month time point, CO, SV, and EF were higher in 266 
Mdx/Utrn+/--Q as compared to Mdx/Utrn+/- and C57 mice. Given these findings, it was not surprising that 267 
LVESD, %FS, SWT, and %SWT were elevated in 10 month old Mdx/Utrn+/--Q as compared to 268 
Mdx/Utrn+/- and C57. T2 mapping images quantified myocardial tissue T2 at the 10 month time point as a 269 
metric of tissue edema. Results indicate a significant rise in T2 value from Mdx/Utrn+/- mice, but no 270 
differences were observed between C57 and Mdx/Utrn+/--Q [Figure 2]. 271 
Western blotting 272 
Western blotting was performed in hearts harvested at the 10 month sacrifice to assess key protein 273 
abundance related to cardiac mitochondrial content, electron transport chain (ETC) complexes, 274 
endogenous antioxidant enzymes, inflammatory signaling, and inflammatory mediators, respectively. 275 
Mitochondrial content - Mean responses for cardiac mitochondrial content (PGC-1α, cytochrome C, and 276 
citrate synthase) and representative blots are presented in [Figure 3A-D]. A pattern of elevated protein 277 
abundance was observed in Mdx/Utrn+/--Q vs Mdx/Utrn+/- for PGC-1α (p<0.001), cytochrome C 278 
(p<0.001), and citrate synthase (p<0.001). Interestingly, hearts from Mdx/Utrn+/--Q exhibited higher 279 
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PGC-1α (p=0.002) and cytochrome C (p=0.033) as compared to C57. ETC complex - Mean responses 280 
for cardiac ETC complex content (complexes I-V) and representative blots are presented in [Figure 4A-281 
F]. Notably, because complex analysis was performed in a single blot with target proteins between 282 
20Kda-57Kda, sample loading was normalized to Ponceau stain lane density within that range of 283 
molecular weights. Importantly, Mdx/Utrn+/--Q exhibited elevated ETC content for complexes I-V, 284 
p<0.001 respectively, compared to Mdx/Utrn+/-. Moreover, as compared to C57, hearts of 10 month old 285 
Mdx/Utrn+/- mice expressed less ETC content for complexes I (p=0.045), III (p=0.007), IV (p=0.012), and 286 
V (p=0.003). Endogenous antioxidant enzymes - Mean responses for cardiac levels of endogenous 287 
antioxidant enzymes (SOD2, and GPX) and representative blots are presented in [Figure 5A-C]. These 288 
selected endogenous antioxidant enzymes are associated with mitochondria content and cardiac health. 289 
SOD2 protein abundance was lower in Mdx/Utrn+/- mice when compared to C57 (p=0.026) and 290 
Mdx/Utrn+/--Q (p=0.004). Furthermore, GPX protein content was higher in Mdx/Utrn+/--Q mice when 291 
compared to both control C57 (p=0.020) and Mdx/Utrn+/- (p=0.003). Inflammatory signaling - Mean 292 
responses for cardiac inflammatory signals (NFκB, P-NFκB, IκBα and P-IκBα) and representative blots 293 
are presented in [Figure 6A-E]. Analyses of blots from 10 month hearts indicate there were no 294 
differences between groups for P-NFκB, IκBα and P-IκBα. In contrast, NFκB protein abundance was 295 
higher in hearts from Mdx/Utrn+/- mice when compared to Mdx/Utrn+/--Q (p=0.010). Inflammatory 296 
mediators - Mean responses for cardiac inflammatory mediators (COX-2, TGF-β, F4/80 and CD64) and 297 
representative blots are presented in [Figure 7A-E]. Analyses of blots from 10 month hearts indicate 298 
there were no group differences for COX-2 or CD64. In contrast, Mdx/Utrn+/--Q expressed lower levels of 299 
TGF-β (p=0.007) and F4/80 (p=0.049) as compared to hearts from Mdx/Utrn+/- mice. 300 
Histology 301 
Histological analyses were performed in hearts harvested at 10 months of age to assess relative protein 302 
abundance and localization related to tissue remodeling and DCG assembly. Tissue remodeling - Mean 303 
histological outcomes for cardiac remodeling (MMP9, fibronectin, and H&E) and representative blots are 304 
presented in [Figure 8A-F]. Analyses of histological cross sections of hearts from all treatments revealed 305 
a common pattern where Mdx/Utrn+/- and Mdx/Utrn+/--Q were higher than C57 for MMP9, fibronectin, 306 
and muscle injury. However, and importantly, analyses also revealed profound cardioprotection in 307 
quercetin treated animals such that mean values from Mdx/Utrn+/--Q mice were substantially and 308 
statistically lower than Mdx/Utrn+/- for MMP9, fibronectin, and muscle injury, respectively. DGC 309 
expression - Mean histological outcomes for restoration of DGC assembly (utrophin, α-sarcoglycan, and 310 
co-localization) and representative images are presented in [Figure 9A-D]. Analyses of histological cross 311 
sections of hearts from all treatments demonstrated a reduction in DGC assembly in Mdx/Utrn+/- and 312 
Mdx/Utrn+/--Q compared to C57 such that utrophin, α-sarcoglycan, and co-localization of the sarcomeric 313 
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proteins were lower in diseased animals compared to control. Excitingly, analyses also indicated that 314 
mean values from Mdx/Utrn+/--Q mice were higher than Mdx/Utrn+/- for utrophin, α-sarcoglycan, and co-315 
localization, respectively, indicating quercetin-mediated restoration of DGC assembly via increased 316 
utrophin abundance and membrane localization. 317 
Spontaneous physical activity 318 
Spontaneous physical activity was observed in diseased mice during the final week of treatment. 319 
Spontaneous total activity counts are presented in Table 3. Analyses indicated similar outcomes for total 320 
activity in that Mdx/Utrn+/--Q mice spent less time sitting and more time socializing, standing, walking, 321 
wall pacing, running, and jumping. During the observation periods both control- and quercetin-fed 322 
Mdx/Utrn+/- mice spent similar times grooming and eating/drinking, the later observation being consistent 323 
with body weight similarities. The activity metric results for all nine observed animal activities are 324 
presented in Figure 10. Findings reveal that Mdx/Utrn+/--Q exhibited significantly more high intensity 325 
physical activity as compared to their control-fed counterparts.  326 




In recent years the incidence of cardiac pathology, including heart failure, has become a significant cause 329 
of morbidity and mortality in DMD patients.(40) In the absence of an available cure and limited 330 
therapeutic approaches, the purpose of this investigation was to pursue a novel and pragmatic therapy to 331 
alleviate DMD pathology. The urgency of therapeutic approaches targeting the heart is underscored by an 332 
array of promising therapies that effectively attenuate disease progression in skeletal muscle, leading to 333 
increased activity and a subsequent cardiac dysfunction. Lifelong 0.2% dietary quercetin enrichment was 334 
examined as a countermeasure to cardiac pathology in the Mdx/Utrn+/- mouse; which is noted for its 335 
relatively severe disease phenotype.(19) Key dependent cardiac outcomes were examined in concert with 336 
a strategic series of post mortem histological and biochemical indices of mitochondrial health, tissue 337 
remodeling, and inflammation. Findings reveal for the first time that long term dietary quercetin 338 
consumption is a potent intervention against cardiac pathology. In addition to improved histological and 339 
biological outcomes in the hearts of quercetin-consuming Mdx/Utrn+/- mice, spontaneous physical activity 340 
was greatly improved and suggests improved mobility. As discussed below, the apparent potency of 341 
quercetin as an intervention against symptomatic disease progression in dystrophic/utrophic mice may 342 
hold important scientific and clinical implications for those with DMD. 343 
Cardiac function 344 
While young dystrophic mice display relatively healthy cardiac function when compared to age matched 345 
controls, dystrophic mice still experience damage due to mechanical overload.(10, 34) Moreover, while 346 
well-studied mdx mouse hearts become fibrotic and exhibit early signs of contractile dysfunction by 9 347 
months of age,(40) pathological onset is delayed as compared to humans with DMD. Accordingly, 348 
Mdx/Utrn+/- murine model is more severe than mdx and was used in the current study to more closely 349 
recapitulate the human disease. Prior investigations report skeletal muscle findings for Mdx/Utrn+/- across 350 
the 2 month-to-10 month age range examined currently,(19) in addition to examination of cardiac 351 
function in the Mdx/Utrn+/- mouse model.(26, 35) These prior studies employed high strength MRI scans 352 
to quantify cardiac function,(26, 35) a methodological approach also used in this investigation. Current 353 
findings indicate strain-specific alterations in EDV in the 2 month scan. In this regard, and related to 354 
conclusions that can be drawn from anesthetized mice where heart rates are suppressed, it should be noted 355 
that HR was higher in both groups of Mdx/Utrn+/- as compared to C57. While this limitation is 356 
acknowledged, similar mouse strain-dependent heart rate differences have been observed in comparable 357 
aged mice (50). Nonetheless, the existence of heart rate differences between groups could have 358 
confounded other cardiac performance variables and possibly interpretation of findings. Accordingly, 359 
whenever possible in future investigations it is recommended that anesthesia be titrated to achieve a 360 
common heart rate between strains and treatments in an effort to avoid this current study limitation. 361 
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Based on the current data and a paucity of published cardiac function data on the Mdx/Utrn+/- mouse, it is 362 
difficult to discern whether these pretreatment EDV values represent animal strain-dependent 363 
developmental differences and/or early remodeling due to dystrophinopathy. Nonetheless, end of study 364 
EDV values were similar between all three groups of mice. Additional research should include additional 365 
dosing strategies (e.g., prevention with early treatment versus recovery by dosing later in life after 366 
dysfunction has occurred) as a way of better understanding the time course of quercetin efficacy 367 
inasmuch as developmental changes in the Mdx/Utrn+/- mouse. Cardiac scans at the end of the 10 month 368 
treatment period indicate the existence of a time-dependent pathology was apparent in untreated 369 
Mdx/Utrn+/- mice as %SWT was greatly decreased compared to control. Given the anesthetized and 370 
unstressed conditions (e.g., independent of β-agonist administration) in which the mice were examined 371 
currently, these findings are in general agreement with a paucity of cardiac function studies in 372 
Mdx/Utrn+/- mice of a similar age.(50) As a means of potentially discerning subtle differences in 373 
treatment- and mouse strain-dependent differences in cardiac function future work with MRI should 374 
explore use of cardiac strain analyses.(35) 375 
An important finding in the current investigation is that in 10 month old Mdx/Utrn+/- mice, quercetin-376 
dependent alterations in cardiac function were observed for many of the variables examined, including 377 
EF, SV, CO, LVESD, %FS, and SWT. These findings are surprising in that alterations appear to be 378 
stimulatory in nature as alterations in cardiac function exceeded that of age-matched C57 mice. The 379 
current study design is limited by the fact that a quercetin treated C57 group was not included. Whether 380 
C57 treated mice would have experienced similar alterations in cardiac function is uncertain, and as such, 381 
this control group should be included in follow-up investigations. While a prior study did not report 382 
quercetin-dependent alterations in cardiac function, methodological differences in the mouse strain, 383 
quercetin dosing and age limit direct comparison (45). The mechanistic underpinnings of these dramatic 384 
findings remain to be determined but may be related to well-described effects of quercetin as a 385 
competitive adenosine receptor antagonist (1). If correct, then quercetin appears to have exerted 386 
ionotropic effects rather than chronotropic alterations in Mdx/Utrn+/- mice. In support, Bartekova et al. 387 
examined quercetin administration as a countermeasure against ischemic injury in doxorubicin treated 388 
mice. In quercetin fed mice, they found HR was similar between groups, but significant alterations in 389 
indices of left ventricular developed pressure, contractility, and relaxation occurred.(4) The importance of 390 
altered cardiac performance in quercetin fed Mdx/Utrn+/- mice are viewed optimistically in light of the 391 
parallel observations that histological, biochemical, and animal activity secondary measures support 392 
quercetin-dependent improvements into senescence.  393 
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Related to cardiac function, both treated and untreated Mdx/Utrn+/- mice were heavier at the end of the 394 
investigation as compared to C57 controls. Additional weight gain could be due to fibrosis and edema 395 
related to dystrophinopathy. In this regard T2 mapping from 10 month cardiac scans were analyzed as a 396 
surrogate marker of myocardial tissue edema, whereby elevated T2 values represent increased tissue 397 
water content. Results indicated that T2 values were elevated in  Mdx/Utrn+/- mice while Mdx/Utrn+/-Q 398 
mice were statistically similar to C57. These findings suggest that hearts receiving dietary quercetin were 399 
less edemic, a preliminary conclusion that is in agreement with histological findings. Thus, we cannot 400 
currently explain the mouse strain-dependent difference in body weight between C57 and both 401 
Mdx/Utrn+/- groups.  402 
Indices of mitochondrial content and oxidative adaptations 403 
Central to our ongoing research line, dietary quercetin enrichment appears to ameliorate many 404 
pathological processes in dystrophic mice via sirtuin1/PGC-1α induction.(3, 22, 24, 38)  Flavanones such 405 
as quercetin stimulate a variety of physiologic pathways including the SIRT1/PGC-1α axis. Published 406 
studies report increased SIRT1/PGC-1α axis gene expression with dietary quercetin feeding,(13, 32) 407 
however findings from the current investigation reveal for the first time that long term quercetin 408 
enrichment also increases cardiac PGC-1α protein expression. Even more intriguing, quercetin 409 
enrichment in Mdx/Utrn+/- mice increased PGC-1α protein expression above that of age matched C57 410 
mice. This latter finding is of particular importance in that heart failure is characterized by decreased 411 
PGC-1α expression and decreased mitochondrial function.(49)  412 
Improved indices of mitochondrial content in quercetin fed Mdx/Utrn+/- mice may represent an important 413 
link between cardiac function and PGC-1α expression. In the current study a series of mitochondrial 414 
related biomarkers were examined in cardiac tissues harvested from 10 month old mice. Findings indicate 415 
that quercetin fed mice exhibited higher abundance of citrate synthase, cytochrome-c, and all electron 416 
transport complexes 1-V (NADH dehydrogenase, succinate dehydrogenase, cytochrome bc1 complex, 417 
cytochrome-C oxidase, and ATP synthase). While not confirmatory, the current data are the first to 418 
quantify elevated markers associated with bioenergetic capacity in the dystrophic hearts of Mdx/Utrn+/- 419 
mice receiving a quercetin enriched diet. Suggestive of pathology inherent to the DMD animal model, 420 
control-fed Mdx/Utrn+/- mice expressed lower abundance of the mitochondrial biomarkers relative to C57 421 
mice. These results emphasize prior observation that dystrophic hearts are susceptible to mitochondrial 422 
damage(47) and bolster our earlier observation that cardiac cytochrome-c levels were higher in young 423 
mdx mice consuming an identical quercetin diet.(3) While the current finding, in addition to recently 424 
published research, suggests that long term quercetin treatment evokes significant metabolic adaptations, 425 
(3, 12) the possibility remains that collective findings may reflect a fiber type shift. Mitochondrial 426 
outcomes in this investigation are intriguing, albeit indirect measures. As such, additional research is 427 
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needed to confirm whether quercetin treatment benefits mitochondrial function. Similar to prior findings 428 
in hearts from dystrophin deficient hearts, future investigations should employ direct markers of 429 
mitochondrial function within a comprehensive panel of secondary indices of mitochondrial health.(18) 430 
Consistent with increased cardiac mitochondrial content, protein expression of the endogenous 431 
antioxidant enzymes SOD2 and GPX were elevated in hearts from Mdx/Utrn+/--Q mice. Although 432 
quercetin possess direct antioxidant properties,(6) quercetin also up-regulates endogenous antioxidant 433 
enzymes.(3, 48) Since SOD2 is primarily located within mitochondria, increased SOD2 levels bolster our 434 
current interpretation that quercetin increased mitochondrial biogenesis in hearts from Mdx/Utrn+/- mice. 435 
Furthermore, GPX overexpression attenuates pathological cardiac remodeling and preserves cardiac 436 
function in mouse hearts.(30, 39)  437 
The reader is cautioned, however, in the interpretation of these findings (absent of glutathione cycling 438 
status) in that alterations in GPX expression may be attributed to redox-induced up-regulation due to 439 
elevated H2O2 production by SOD2. Additional experimentation is needed before firm conclusions about 440 
redox status of treated hearts can be conclusively attributed to quercetin consumption. Nonetheless, 441 
outcomes from microarray gene profiling experiments of primary cardiomyocytes incubated with 442 
quercetin indicate that a host of antioxidant and antioxidant related genes are up-regulated (2). In 443 
combination with the anti-inflammatory and anti-proteolytic effects of quercetin on cardiac architecture, a 444 
rationale exists that quercetin may also influence phenotypic shifts in fiber type. To our knowledge this 445 
latter point is currently untested and should be the focus of additional research efforts.  446 
DGC protein expression 447 
Among the most compelling findings of the current investigation is the observation that long term 448 
quercetin feeding of Mdx/Utrn+/- mice resulted in improved histological indices of utrophin and α-449 
sarcoglycan. Moreover, protein expression of these fundamental structural proteins appear to be co-450 
localized at the sarcolemma in greater abundance in hearts from quercetin fed mice than in mice 451 
maintained on a control diet. These findings are remarkable given the nature of the heterozygous 452 
knockout of the utrophin gene in the Mdx/Utrn+/- mouse and support our previous finding of quercetin-453 
related utrophin over expression in mdx mice.(3) Collective findings in the current study are of particular 454 
importance in that the real benefit in utrophin up-regulation is dependent upon its role in restoration of the 455 
DGC. While current findings are semi-quantitative, these data suggest that quercetin enrichment aids in 456 
DCG reassembly in the dystrophic heart. 457 
Fibrosis and damage 458 
Histological indices for tissue remodeling reveal strong evidence that long term quercetin feeding of 459 
Mdx/Utrn+/- mice lead to profound improvements in age-dependent attenuation in histological remodeling 460 
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measures of MMP9, fibronectin, and H&E staining. These findings support our prior work in aged mdx 461 
mice exposed to an identical quercetin feeding regimen(3) and emphasize the value of dietary polyphenol 462 
use as anti-fibrotic agents.(20, 25) Moreover, current results are in agreement with previous findings that 463 
suggest quercetin inhibits MMP9 directly and may also be related to mito- and cyto- protection due to 464 
structure–activity analysis demonstrating that flavonoid R3–OH and R4–OH substitutions contribute to 465 
MMP9 inhibitory properties.(28, 36) Notably, improvements in quercetin fed Mdx/Utrn+/- mice were not 466 
statistically equal to age-matched C57 counterparts. Whether lifetime quercetin feeding (i.e., prior to our 467 
2 month treatment initiation) would have fully attenuated indices of remodeling is uncertain. To better 468 
resolve these uncertainties, gross quantification of histological outcomes should be included in future 469 
investigations. Nonetheless, complete attenuation pathological remodeling appears unlikely given that 470 
remodeling has been observed in younger mdx mice with a less severe dystrophic phenotype.(40) In 471 
addition, greater therapeutic effects may be found by combining this quercetin intervention and a 472 
complementary intervention with an independent mode of action.  473 
Indices of inflammatory signaling and mediation 474 
We observed that quercetin feedings of Mdx/Utrn+/- mice had a modest outcome for attenuation of 475 
inflammatory signaling and mediation. This study arm is important given that DMD exhibits multi-476 
faceted physiological maladaptive consequences due to chronic inflammation. Specifically, quercetin 477 
enrichment was examined for NFκB pathway activity in Mdx/Utrn+/- hearts. In agreement with a prior 478 
finding,(31) total NFκB protein abundance was lower with quercetin feeding, although quercetin 479 
enrichment did not alter other examined aspects of the pathway including cardiac levels of IKBα, P-480 
IKBα, and P-NFκB. These largely negative outcomes may be limited by sample collection at a single end 481 
point where dynamic signaling changes could not be observed. Accordingly, downstream mediators of 482 
NFκB pathway activation (COX-2) and related inflammatory mediators (TGFβ-1, F4/80, and CD64) were 483 
also observed. COX 2 protein abundance was ~50% lower in quercetin fed versus control-fed Mdx/Utrn+/- 484 
mice, although this finding failed to reach statistical significance. In contrast, TGFβ-1 expression was 485 
attenuated with quercetin feeding and supports a previous finding that quercetin blunts fibroblast 486 
signaling. (33) Collective findings for TGFβ-1 also bolster the observations of decreased fibronectin 487 
expression and cardiac damage in hearts from quercetin fed mdx/Utrn+/- mice. Finally, CD64 and F4/80 488 
were examined as indices of macrophages and immune cell infiltration. Quercetin enrichment did not 489 
alter CD64 expression, but was associated with decreased F4/80 protein expression. In concert, these 490 
results may suggest that immune cell infiltration in inflammatory signaling decreased, but that any 491 
benefits due to dietary quercetin enrichment were modest by comparison to other aspects of this 492 
comprehensive investigation.  493 
Spontaneous activity in Mdx/Utrn+/- mice 494 
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Quercetin treatment elicited significantly more high intensity spontaneous activity in that quercetin-fed 495 
mice performed significantly more moderate intensity (socializing and walking) and high intensity (wall 496 
pacing, running, and jumping) activity as compared to control-fed Mdx/Utrn+/- mice. Conversely, 497 
quercetin-fed mice spent less time sitting. It is important to note that activity scores were averaged across 498 
observation periods within the respective dark and light housing cycles. When time-normalized activity 499 
counts were scaled for metabolic intensity and incorporated into a single metric, where higher scores 500 
reflect more time spent in high intensity activity, it was confirmed that quercetin-fed mice were 501 
significantly more active at 10 months of age. This finding of improved physical activity is of vital 502 
interest in that 10 month old Mdx/Utrn+/- mice are near the end of their natural lifespan.(46) Anecdotally, 503 
activity levels in quercetin fed mice are also higher than 14 month old C57 mice (data not shown 504 
currently) and reinforce the aforementioned notion that quercetin may act as an adenosine receptor 505 
antagonist. Admittedly, the current investigation is limited by the fact that age matched activity data are 506 
not available in C57 mice. Nonetheless, when reflected against the other benefits attributed to quercetin 507 
consumption in the current animal-based investigation, improved spontaneous physical activity may hold 508 
the most important implications for clinical populations. Furthermore, it is important to recognize broad 509 
quercetin-mediated protection in spite of increased activity, which has been linked to negative cardiac 510 
outcomes even in cage sedentary animals.(44) Whether the improved cardiac outcomes were due to 511 
altered physical activity or the impetus for mice to be more active cannot be determined at this time. In 512 
follow-up investigations additional mid-study examination of cardiac function and physical activity are 513 
recommended to better delineate the cause and effect of these physiologic outcomes.  514 
Conclusion 515 
While multiple published studies reveal flavanone and polyphenol consumption benefits cardiac aging 516 
and function,(42, 43) the current investigation is the first to demonstrate that long-term quercetin 517 
consumption alleviates cardiac dysfunction in a pathologically severe Mdx/Utrn+/- mouse model of DMD. 518 
In addition to the longitudinal approach, this comprehensive data set encompasses physiologic, 519 
histological, and biochemical outcomes measured concurrently. Findings reveal that long term dietary 520 
quercetin feeding robustly protects against the development of cardiac dysfunction in the Mdx/Utrn+/- 521 
mouse. Post mortem cardiac tissue histological and biochemical analyses indicate that quercetin 522 
enrichment exerted dramatic improvements in cardiac remodeling and mitochondrial protein markers for 523 
oxidative enzymes and endogenous antioxidant enzymes. These noteworthy results bolster our previous 524 
investigations using similar methodological approaches in the mdx mouse model of DMD. Collective 525 
findings suggest that dietary quercetin consumption exerts pleiotropic benefits in cardiac function that 526 
may also extend to improvements in spontaneous physical activity. Of note, these data stand in stark 527 
contrast to our recent findings in skeletal muscle where quercetin-mediated protection was transient with 528 
18 
 
advancing age.(37) We present compelling, albeit indirect, evidence to suggest that increased PGC-1α 529 
expression underpins the cardioprotective benefits observed in quercetin fed animals. While no single 530 
therapeutic agent exists to attenuate age-dependent cardiac dysfunction in dystrophic hearts, current 531 
results suggest that quercetin enrichment may be a novel counter therapy against dystrophic 532 
cardiopathology. Further investigation is required to resolve whether dietary quercetin enrichment also 533 
holds therapeutic potential for DMD patients.  534 
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Figure 1. Representative images of MRI heart scans in 10 month old mice. Representative T1 dark-692 
blood cine images of MRI heart scans in 10 month old mice. Images include mid-ventricular short-axis 693 
views at end-diastole and end-systole time frames from C57 (C57BL/10SnJ), Mdx/Utrn+/-, and 694 
Mdx/Utrn+/--Q mice. N=6-8/group.  695 
 696 
Figure 2. T2 weighted images from cardiac MRI scans in 10 month old C57 and Mdx/Utrn+/- mice.  697 
T2 weighted images from cardiac MRI scans in 10 month old mice were quantified as an indirect measure 698 
of tissue edema. Data are means ± SEM. * denotes significantly different from C57 (C57BL/10SnJ), # 699 
denotes significantly different from Mdx/Utrn+/-. 700 
 701 
Figure 3. Protein abundance of markers of mitochondrial content from 10 month heart tissue. A) 702 
PGC-1α abundance, B) Cytochrome-C abundance, C) Citrate Synthase abundance, and D) representative 703 
blots for target proteins and normalization proteins. Samples were derived from ventricular tissue of C57 704 
(C57BL/10SnJ), Mdx/Utrn+/-, and Mdx/Utrn+/--Q mice. N=6-8/group. Data are means ± SEM. * denotes 705 
significantly different from C57,  # denotes significantly different from Mdx/Utrn+/-. 706 
 707 
Figure 4. Protein abundance of electron transport complexes from 10 month heart tissue.  708 
A) Complex 1 abundance, B) Complex 2 abundance, C) Complex 3 abundance, D) Complex 4 709 
abundance, E) Complex 5 abundance, and F) representative blots and ponceau stained normalization blot. 710 
Samples were derived from ventricular tissue of C57 (C57BL/10SnJ), Mdx/Utrn+/-, and Mdx/Utrn+/--Q 711 
mice. N=6-8/group. Data are means ± SEM. # denotes significantly different from Mdx/Utrn+/-. 712 
 713 
Figure 5. Protein abundance of endogenous antioxidant enzymes from 10 month heart tissue.  714 
A) SOD2 abundance, B) GPX abundance, and C) representative blots and normalization proteins. 715 
Samples were derived from ventricular tissue of C57 (C57BL/10SnJ), Mdx/Utrn+/-, and Mdx/Utrn+/--Q 716 
mice. N=6-8/group. Data are means ± SEM. * denotes significantly different from C57, # denotes 717 
significantly different from Mdx/Utrn+/-. 718 
 719 
Figure 6. Protein abundance of inflammatory signaling markers from 10 month heart tissue.  720 
A) NFκB abundance, B) P-NFκB abundance, C) IκBα abundance, D) P-IκBα abundance, and E) 721 
representative and normalization protein blots. Samples were derived from ventricular tissue of C57 722 
(C57BL/10SnJ), Mdx/Utrn+/-, and Mdx/Utrn+/--Q mice. N=6-8/group. Data are means ± SEM. * denotes 723 






Figure 7. Protein abundance of inflammatory mediators from 10 month heart tissue.  728 
A) COX-2, B) TGF-β1, C) F4/80, D) CD64 abundance, and E) representative and normalization protein 729 
blots. Samples were derived from ventricular tissue of C57 (C57BL/10SnJ), Mdx/Utrn+/-, and Mdx/Utrn+/-730 
-Q mice. N=6-8/group. Data are means ± SEM. * denotes significantly different from C57, # denotes 731 
significantly different from Mdx/Utrn+/-. 732 
 733 
Figure 8. Histological indices of remodeling from 10 month heart tissue.  734 
A) MMP9 mean densities, B) representative fluorescent micrographs for MMP9, C) fibronectin mean 735 
densities, D) representative fluorescent micrographs for fibronectin, E) hematoxylin and eosin mean 736 
densities, and F) representative fluorescent micrographs for hematoxylin and eosin. Samples were derived 737 
from ventricular cross sections of C57 (C57BL/10SnJ), Mdx/Utrn+/-, and Mdx/Utrn+/--Q mice. N=6-738 
8/group. Data are means ± SEM. * denotes significantly different from C57, # denotes significantly 739 
different from Mdx/Utrn+/-. 740 
 741 
Figure 9. Histological indices of utrophin expression from 10 month heart tissue.  742 
A) utrophin mean densities, B) α-sarcoglycan mean densities, C) utrophin-α-sarcoglycan colocalization 743 
mean densities, D) representative fluorescent micrographs for DAPI (nuclei), FITC (utrophin), TRITC (α-744 
sarcoglycan), FITC+TRITC, and computer merged images of DAPI+FITC+TRITC images. Samples were 745 
derived from ventricular cross sections of C57 (C57BL/10SnJ), Mdx/Utrn+/-, and Mdx/Utrn+/--Q mice. 746 
N=6-8/group. Data are means ± SEM. * denotes significantly different from C57, # denotes significantly 747 
different from Mdx/Utrn+/-. 748 
 749 
Figure 10. Spontaneous activity metric scores in Mdx/Utrn+/- mice.  750 
Composite spontaneous activity score scaled for relative metabolic intensity of sitting, grooming, 751 
eating/drinking, socializing, standing, walking, wall pacing, running, and jumping. Scores represent 752 
average activity counts during light and dark housing cycles in Mdx/Utrn+/- and Mdx/Utrn+/--Q mice. 753 
N=6-8/group. Data are means ± SEM. # denotes significantly different from Mdx/Utrn+/-. 754 
26 
 
Table 1. Animal Characteristics at 10 months 755 
Strain Body Weight (g) Absolute Heart Weight 
(mg) 
Relative Heart Weight 
(mg/g) 
C57 30.8 ± 2.50 162 ± 11.45  5.2 ± 0.33 
Mdx/Utrn+/- 41.2 ± 2.73 * 194 ± 15.31* 4.8 ± 0.38 
Mdx/Utrn+/--Q 42.0 ± 2.34 * 183 ± 13.6 4.4 ± 0.42 * 
N=6-8/group. Data are means ± SEM; * denotes significantly different from C57. 756 
 757 
 758 
  759 
27 
 
Table 2. Cardiac Function 760 
Time Strain HR 
(bpm) 






















C57 333.5±7.4 52.3±2.8 40.7±2.3 14241±422 78.5±0.9 38.3±2.3 3.74±0.04 2.25±0.11 40.0±2.7 0.39±0.05 30.3±2.3 
Mdx/Utrn+/- 376.5±6.4* 54.5±2.0 33.1±2.1 12443±844 59.3±3.5* 27.5±1.8 3.07±0.13 1.71±0.09* 44.1±2.2 0.36±0.05 24.0±2.8 
Mdx/Utrn+/--Q 387.1±8.5* 51.8±3.5 35.4±1.8 13105±558 66.8±4.3* 33.2±3.9 3.26±0.17 1.98±0.18 39.7±3.6 0.35±0.05 26.1±2.8 
10 
month 
C57 314.2±14.7 53.9±3.2 45.0±2.4 14308±1320 84.5±3.4 39.5±4.4 3.91±0.08 2.21±0.16 43.8±3.0 0.57±0.04 36.2±2.4 
Mdx/Utrn+/- 360.0±3.3*  51.0±1.8  41.4±2.4ǂ 14910±555 84.5±3.8ǂ 41.5±3.0ǂ  3.71±0.09 2.26±0.13ǂ  39.3±2.5  0.47±0.04 28.3±2.6*  
Mdx/Utrn+/--Q 370.1±7.2*  62.5±4.4#ǂ 52.7±2.0*#ǂ 19852±2818*#ǂ  81.6±3.3ǂ 29.4±3.8 3.55±0.18 1.51±0.11*# 52.8±5.3*#ǂ 0.70±0.06#ǂ 37.4±2.5#ǂ 
Heart rate (HR), left ventricular ejection fraction (LV EF), stroke volume (SV), cardiac output (CO), end diastolic volume (EDV), end systolic 761 
volume (ESV), left ventricular end diastolic dimension (LVEDD), left ventricular end systolic dimension (LVESD), left ventricular fractional 762 
shortening (LV FS), systolic wall thickness (SWT); N=6-8/group. Data are means ± SEM; * denotes significantly different from age matched C57; 763 
# denotes significantly different from age matched Mdx/Utrn+/-; ǂ denotes significantly different from 2 month baseline value. 764 
 765 
  766 
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N=6-8/group. Data are means ± SEM; * denotes significantly different from age matched C57; ǂ denotes significantly different from 2 month 768 
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PGC-1α                                                   90KDa 
 
     C57         Mdx/Utrn+/-   Mdx/Utrn+/--Q                                            
 
Cytochrome C          20 KDa 
 
α-Tubulin             50KDa 
 
Citrate 
Synthase             52 KDa  
GAPDH            37 KDa 
Figure 4 
 







































































































     C57         Mdx/Utrn+/-   Mdx/Utrn+/--Q                                            
I                                                       20 KDa  
II                                                      30 KDa  
III               49 KDa  
IV               40 KDa  








































     C57         Mdx/Utrn+/-   Mdx/Utrn+/--Q                                             
SOD2        25 KDa  
α-Tubulin             50 KDa 
 
GPX                  23 KDa  











































































NFκB                65 KDa 
E)       C57         Mdx/Utrn+/-   Mdx/Utrn+/--Q                                            
 
P-NFκB       65 KDa  
IκBα             39 KDa  
P-IκBα     40 KDa  
α-Tubulin         50 KDa 
Figure 7 
 





C)                                                                             D) 







































































    COX-2      74 KDa 
  TGF-1β      12 KDa 
      F4/80      160 KDa 
      CD64      43 KDa 
α-Tubulin       50 KDa 
E)  
     C57         Mdx/Utrn+/-   Mdx/Utrn+/--Q                                            
Figure 8 
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